Crossmark

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

Crossref DOI link: https://doi.org/10.1016/j.reuma.2018.07.009

Published Print: 2020-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Blanco, Francisco J.

Rubio-Romero, Esteban

Sanmartí, Raimon

Díaz-Torné, César

Talavera, Pablo

Dunkel, Jochen

Naredo, Esperanza
Funding

Funding for this research was provided by:

UCB Pharma
License Information

Text and Data Mining valid from 2020-09-01

Version of Record valid from 2018-10-03
More Information

This article is maintained by: Elsevier

Article Title: Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure

Journal Title: Reumatología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reuma.2018.07.009

Content Type: article

Copyright: © 2018 The Authors. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below